Initial Statement of Beneficial Ownership (3)
February 25 2021 - 6:04PM
Edgar (US Regulatory)
FORM 3
|
UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
INITIAL STATEMENT OF BENEFICIAL OWNERSHIP OF SECURITIES
|
OMB APPROVAL
OMB Number:
3235-0104
Estimated average burden
hours per response...
0.5
|
|
Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940
|
|
|
1. Name and Address of Reporting Person
*
Roshwalb Gur |
2. Date of Event Requiring Statement (MM/DD/YYYY)
2/24/2021
|
3. Issuer Name and Ticker or Trading Symbol
SUNESIS PHARMACEUTICALS INC [VIRX]
|
|
(Last)
(First)
(Middle)
C/O VIRACTA THERAPEUTICS, INC., 2533 S COAST HWY 101, SUITE 210 |
4. Relationship of Reporting Person(s) to Issuer (Check all applicable)
__X__ Director ___X___ 10% Owner
_____ Officer (give title below) _____ Other (specify below)
|
|
(Street)
CARDIFF, CA 92007
(City)
(State)
(Zip)
| 5. If Amendment, Date Original Filed(MM/DD/YYYY)
| 6. Individual or Joint/Group Filing(Check Applicable Line)
_X_ Form filed by One Reporting Person
___ Form filed by More than One Reporting Person
|
Table I - Non-Derivative Securities Beneficially Owned
|
1.Title of Security
(Instr. 4) | 2. Amount of Securities Beneficially Owned
(Instr. 4) | 3. Ownership Form: Direct (D) or Indirect (I)
(Instr. 5) | 4. Nature of Indirect Beneficial Ownership
(Instr. 5) |
| Common Stock | 2032865 | I | See Footnote (1) |
| Common Stock | 5359372 | I | See Footnote (2) |
Table II - Derivative Securities Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
|
1. Title of Derivate Security
(Instr. 4) | 2. Date Exercisable and Expiration Date
(MM/DD/YYYY) | 3. Title and Amount of Securities Underlying Derivative Security
(Instr. 4) | 4. Conversion or Exercise Price of Derivative Security | 5. Ownership Form of Derivative Security: Direct (D) or Indirect (I)
(Instr. 5) | 6. Nature of Indirect Beneficial Ownership
(Instr. 5) |
| Date Exercisable | Expiration Date | Title | Amount or Number of Shares |
| Explanation of Responses: |
| (1) | Shares are owned directly by aMoon - VRCT SPV Limited Partnership, for which the reporting person may be deemed to have voting and dispositive power. The reporting person disclaims beneficial ownership of such shares except to the extent of his pecuniary interest therein, if any. |
| (2) | Shares are owned directly by aMoon 2 Fund Limited Partnership, for which the reporting person may be deemed to have voting and dispositive power. The reporting person disclaims beneficial ownership of such shares except to the extent of his pecuniary interest therein, if any. |
Remarks:
Exhibit 24: Power of Attorney |
Reporting Owners
|
| Reporting Owner Name / Address | Relationships |
| Director | 10% Owner | Officer | Other |
Roshwalb Gur
C/O VIRACTA THERAPEUTICS, INC.
2533 S COAST HWY 101, SUITE 210
CARDIFF, CA 92007 | X | X |
|
|
Signatures
|
| /s/ Michael Mueller, as Attorney-in-Fact | | 2/24/2021 |
| **Signature of Reporting Person | Date |
Sunesis Pharmaceuticals (NASDAQ:SNSS)
Historical Stock Chart
From Mar 2024 to Apr 2024
Sunesis Pharmaceuticals (NASDAQ:SNSS)
Historical Stock Chart
From Apr 2023 to Apr 2024
